Please assess the completion status of the following clinical trial:

Trial Title: Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with relapsed/refractory, biopsy-proven primary cutaneous T-cell lymphoma who have received at least two previous standard systemic therapies and, if MF/SS, is stage IB IVB at study entry.~2. Centrally assessed KIR3DL2 expression on tumor cells.~3. Patients must have the following minimum wash-out from previous treatments:~   * ≥12 weeks for total skin electron beam irradiation,~  * ≥4 weeks for monoclonal antibodies (≥8 weeks for alemtuzumab),~  * ≥3 weeks for local radiation therapy, systemic cytotoxic anticancer therapy, treatment with other anti-neoplastic investigational agents~  * ≥3 weeks for systemic retinoids, interferons, vorinostat, romidepsin, fusion proteins~  * ≥3 weeks for phototherapy~  * ≥2 weeks for topical therapy (including steroids, retinoids, nitrogen mustard or imiquimod) Topical steroids (maximum strength: medium potency) and oral steroids (≤10 mg prednisone equivalent/day) are allowed, if the patient has been on a stable dose with stable symptoms for at least 4 weeks prior to study entry.~4. At least 18 years of age.~5. ECOG performance status of ≤2.~6. Adequate baseline laboratory data: hemoglobin \>9 g/dL, absolute neutrophil count (ANC) ≥1,000/µL, CD4+ T-cells ≥200/µL, platelets ≥50,000/µL, bilirubin ≤1.5 X upper limit of normal (ULN) or ≤3 X ULN for patients with Gilbert's disease, serum creatinine ≤1.5 X ULN, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3 X ULN.~7. Women of childbearing potential (WOCBP) must have a negative serum beta-HCG pregnancy test result within seven days of treatment and must practice an effective method of contraception during treatment and for at least 9 months (270 days) following the last dose of study drug.~8. Female patients who are post-menopausal or surgically sterile.~9. Male patients who agree to practice effective barrier contraception.~10. Ability to understand and the willingness to sign a written informed consent document.~11. No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.~Exclusion Criteria:~1. Patients with limited disease (if MF/SS: stages IA) or central nervous system (CNS) disease.~2. Clinical relevant AEs or laboratory results related to previous anti-neoplastic therapy have not resolved to a NCI-CTCAE grade ≤1.~3. Concomitant corticosteroid use, systemic or topical, for treatment of skin disease. However, topical steroids (maximum strength: medium potency) and oral steroids (≤10 mg prednisone equivalent/day) are allowed, if patient has been on a stable dose with stable symptoms for at least 4 weeks prior to study entry.~4. Patients who have undergone major surgery \<4 weeks prior to starting study drug.~5. Patients who have undergone a stem cell transplantation.~6. Patients with known NCI CTCAE Grade 3 or higher (requiring IV antibiotics) active systemic or cutaneous viral, bacterial, or fungal infection.~7. Patients who are Hepatitis B or Hepatitis C antibody positive.~8. Patients who are known to be HIV-positive.~9. Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.~10. Patients with a history of other malignancies during the past three years. (The following are exempt from the three-year limit: non-melanoma skin cancer, Lymphomatoid papulosis, curatively treated localized prostate cancer, curatively treated localized breast cancer, resected thyroid cancer, biopsy proven cervical intraepithelial neoplasia or cervical carcinoma in situ).~11. Patients who are currently pregnant or breastfeeding.~12. Patients with congestive heart failure, Class III or IV, by New York Heart Association (NYHA) criteria.~13. Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment.~14. Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPH4102 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete